Genzyme returns to growth in Q3
This article was originally published in Scrip
Executive Summary
Genzyme has furthered its cause for a higher takeover offer from Sanofi-Aventis after it returned to revenue and income growth in the third-quarter and highlighted its efforts to remedy its manufacturing setbacks.